As the COVID-19 pandemic continues to affect people worldwide, the need for accurate and specific coding of COVID-19 diagnoses and procedures has become increasingly important. The Centers for Disease Control and Prevention (CDC) and the Centers for Medicare and Medicaid Services (CMS) have released new guidelines and updates to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) and Procedure Coding System (ICD-10-PCS) to reflect the evolving nature of the pandemic. In this article, we will discuss some of the new COVID-19 diagnosis and procedure codes guidelines for 2023.
ICD-10-CM Guidelines
-
COVID-19 Diagnosis Codes
There are several diagnosis codes related to COVID-19, including codes for confirmed cases, suspected cases, exposure to COVID-19, and sequela (long-term effects) of COVID-19. For 2023, the CDC has added several new codes to reflect the latest updates to COVID-19 diagnosis and treatment:
- U10.1: COVID-19, virus identified
- U10.2: COVID-19, virus not identified
- U10.3: Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19
- U10.4: Post-COVID-19 condition, unspecified
- U10.5: Post-COVID-19 condition, long-term
- U10.6: Post-COVID-19 condition, acute
-
COVID-19 Testing Codes
There are several codes related to COVID-19 testing, including codes for laboratory tests, antigen tests, and antibody tests. For 2023, the CDC has added a new code to reflect the use of at-home COVID-19 tests:
- Z11.53: Encounter for screening for COVID-19 with an at-home COVID-19 test
-
COVID-19 Vaccine Codes
There are several codes related to COVID-19 vaccines, including codes for the vaccine product, administration, and adverse effects. For 2023, the CDC has added a new code to reflect the administration of a booster dose of the COVID-19 vaccine:
- Z23.44: Encounter for booster dose of COVID-19 vaccine
ICD-10-PCS Guidelines
-
COVID-19 Procedure Codes
There are several procedure codes related to COVID-19 treatment and management, including codes for ventilation, extracorporeal membrane oxygenation (ECMO), and convalescent plasma therapy. For 2023, the CMS has added several new codes to reflect the latest updates to COVID-19 treatment and management:
- 5A1221Z: Administration of oral antiviral medication for treatment of COVID-19
- 5A1321Z: Administration of intravenous antiviral medication for treatment of COVID-19
- 5A1421Z: Administration of monoclonal antibody for treatment of COVID-19
- 5A1521Z: Administration of combination monoclonal antibody for treatment of COVID-19
- 5A1621Z: Administration of convalescent plasma for treatment of COVID-19
-
Telehealth Procedure Codes
Telehealth has become an important tool in managing the COVID-19 pandemic, allowing patients to receive care remotely. For 2023, the CMS has added several new telehealth procedure codes to reflect the increased use of telehealth:
- 8E0F0ZZ: Encounter for telehealth visit for evaluation and management, initial
- 8E0F4ZZ: Encounter for telehealth visit for evaluation and management, subsequent
- 8E0F8ZZ: Encounter for telehealth visit for evaluation and management, follow-up